Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study

Vaccine

Volumn 31, Issue 37, 2013, Pages 3863-3871

  Brisson, Marc ^a,b,c   Laprise, Jean François ^a   Drolet, Mélanie ^a,b   Van de Velde, Nicolas ^a,b   Franco, Eduardo L ^d   Kliewer, Erich V ^e,f,g   Ogilvie, Gina ^h   Deeks, Shelley L ⁱ   Boily, Marie Claude ^c  

^a Université Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g Epidemiology and Cancer Registry   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

Cervical cancer; Cost effectiveness; Economic analysis; HPV vaccination; Mathematical modeling

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANADA; CANCER PREVENTION; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; FEMALE; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HERD IMMUNITY; HUMAN; IMMUNIZATION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEXUAL BEHAVIOR; VIRUS TRANSMISSION;

CERVICAL CANCER; COST-EFFECTIVENESS; ECONOMIC ANALYSIS; HPV VACCINATION; MATHEMATICAL MODELING;

CANADA; CHILD; CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; MALE; MODELS, ECONOMIC; MODELS, THEORETICAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SEXUAL BEHAVIOR; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84881551412     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.064     Document Type: Article

References (83)

1. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
2. Garland S.M., Steben M., Sings H.L., James M., Lu S., Railkar R., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009, 199:805-814.
3. Pou A.M., Rimell F.L., Jordan J.A., Shoemaker D.L., Johnson J.T., Barua P., et al. Adult respiratory papillomatosis: human papillomavirus type and viral coinfections as predictors of prognosis. Ann Otol Rhinol Laryngol 1995, 104:758-762.
4. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens. Part B. Biological agents. Lancet Oncol 2009, 10:321-322.
5. Backes D.M., Kurman R.J., Pimenta J.M., Smith J.S. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009, 20:449-457.
6. De Vuyst H., Clifford G.M., Nascimento M.C., Madeleine M.M., Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124:1626-1636.
7. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14:467-475.
8. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
9. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
10. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
11. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007, 356:1928-1943
12. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:781-789.
13. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011, 7:1343-1358.
14. Erickson L.J., De Wals P., Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005, 23:2470-2476.
15. Brisson M., Van de Velde N., Boily M.C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351.
16. Kim J.J., Brisson M., Edmunds W.J., Goldie S.J. Modeling cervical cancer prevention in developed countries. Vaccine 2008, 26(Suppl. 10):K76-K86.
17. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.
18. Lee V.J., Tay S.K., Teoh Y.L., Tok M.Y. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health 2011, 11:203.
19. Dee A., Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010, 20:213-219.
20. Brisson M., Van de Velde N., De Wals P., Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007, 25:5399-5408.
21. Kohli M., Lawrence D., Haig J., Anonychuk A., Demarteau N. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada. BMC Public Health 2012, 12:872.
22. Westra T.A., Stirbu-Wagner I., Dorsman S., Tutuhatunewa E.D., de Vrij E.L., Nijman H.W., et al. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis 2013, 13:75.
23. Van de Velde N., Brisson M., Boily M.C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28:5473-5484.
24. Van de Velde N., Boily M.C., Drolet M., Franco E.L., Mayrand M.H., Kliewer E.V., et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012, 104:1712-1723.
25. Brisson M, Van de Velde N, Drolet M, Boily MC, Franco EL, Mayrand MH, et al. HPV-advise: technical appendix to J Natl Cancer Inst 2012; http://wwwmarc-brissonnet/HPVadvisepdf.
26. Laprise J.F., Drolet M., Van de Velde N., Malagon T., Boily M.C., Brisson M. Efficacité populationnelle et coÛt-efficacité des programmes de vaccination contre les VPH au Québec. Report submitted to the Institut National de Santé Publique du Québec (INSPQ) 2012.
27. Shepard D.S. Cost-effectiveness in health and medicine 1999, Oxford University Press, New York. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein (Eds.).
28. Pitman R., Fisman D., Zaric G.S., Postma M., Kretzschmar M., Edmunds J., et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-5. Med Decis Making 2012, 32:712-721.
29. WHO Investing in health for economic development. Report of the commission on macroeconomics and health 2001, WHO, Geneva, Switzerland.
30. WHO WHO-CHOICE: World Health Organization statistical information system: choosing interventions that are cost effective 2006.
31. Ministère de la Santé et des Services Sociaux du Québec (MSSS). Vigie - Interventions: Couverture vaccinale en milieu scolaire. Flash Vigie 2010, 5:1-2.
32. Statistics Canada Canadian Community Health Survey (CCHS - Cycle 3.1) 2005, Available at [accessed January 2011]. www.statcan.gc.ca
33. Drolet M., Brisson M., Maunsell E., Franco E.L., Coutlee F., Ferenczy A., et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology 2012, 21:1071-1081.
34. Drolet M., Brisson M., Maunsell E., Franco E.L., Coutlee F., Ferenczy A., et al. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis 2011, 38:949-956.
35. Demers A., Kliewer E.V., Musto G., Butler J., Elliot L., Shearer B., et al. Epidemiology of cervical abnormalities and utilization of related health care resources 2009, 49. CancerCare Manitoba, Winnipeg.
36. Ades S., Koushik A., Duarte-Franco E., Mansour N., Arseneau J., Provencher D., et al. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 2008, 122:2820-2826.
37. Richardson H., Kelsall G., Tellier P., Voyer H., Abrahamowicz M., Ferenczy A., et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003, 12:485-490.
38. Mayrand M.H., Duarte-Franco E., Coutlee F., Rodrigues I., Walter S.D., Ratnam S., et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer 2006, 119:615-623.
39. Coutlee F., Ratnam S., Ramanakumar A.V., Insinga R.R., Bentley J., Escott N., et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011, 83:1034-1041.
40. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128:927-935.
41. Liu S., Semenciw R., Probert A., Mao Y. Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer 2001, 11:24-31.
42. Public Health Agency of Canada. Cancer surveillance on-line. Available at [accessed January 2011]. http://dsol-smed.phac-aspc.gc.ca/dsol-smed/cancer/index-eng.php.
43. Cancer Agency B.C. Cervical cancer screening program. 2009 annual report 2009, Vancouver, BC, Available at http://www.bccancer.bc.ca [accessed January 2011].
44. Kliewer E.V., Demers A.A., Elliott L., Lotocki R., Butler J.R., Brisson M. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009, 36:380-386.
45. Naud P. Sustained immunogenicity and efficacy of the HPV-16/18 vaccine in women aged 15-25 years: follow-up to 9.4 years. Abstract presented at the 27th international papillomavirus conference and clinical workshop 2011.
46. Gold M.R., Franks P., McCoy K.I., Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36:778-792.
47. Institute of Medicine of the National Academies Vaccines for the 21st century: a tool for decision making 1999, Available at http://www.iom.edu/Reports/1999/Vaccines-for-the-21st-Century-A-Tool-for-Decisionmaking.aspx [accessed January 2011].
48. Rogers S.N., Miller R.D., Ali K., Minhas A.B., Williams H.F., Lowe D. Patients' perceived health status following primary surgery for oral and oropharyngeal cancer. Int J Oral Maxillofac Surg 2006, 35:913-919.
49. Anonychuk A.M., Bauch C.T., Merid M.F., Van Kriekinge G., Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009, 9:401.
50. Vijayaraghavan A., Efrusy M.B., Mayrand M.H., Santas C.C., Goggin P. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. Can J Public Health 2010, 101:220-225.
51. Kulasingam S.L., Rajan R., St Pierre Y., Atwood C.V., Myers E.R., Franco E.L. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med 2009, 7:69.
52. Marra F., Ogilvie G., Colley L., Kliewer E., Marra C.A. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2009, 85:111-115.
53. Benedet J.L., Bertrand M.A., Matisic J.M., Garner D. Costs of colposcopy services and their impact on the incidence and mortality rate of cervical cancer in Canada. J Low Genital Tract Dis 2005, 9:160-166.
54. Kim J.J., Goldie S.J. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009, 339:b3884.
55. Hu D., Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008, 198:500 e1-e5007.
56. NCI Surveillance epidemiology and end results national institutes of health 2006, National Cancer Institute (NCI).
57. Sheldon T.A. Discounting in health care decision-making: time for a change. J Public Health Med 1992, 14:250-256.
58. Beutels P., Scuffham P.A., MacIntyre C.R. Funding of drugs: do vaccines warrant a different approach. Lancet Infect Dis 2008, 8:727-733.
59. Westra T.A., Parouty M., Brouwer W.B., Beutels P.H., Rogoza R.M., Rozenbaum M.H., et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health 2012, 15:562-567.
60. Public Health Agency of Canada Recommendations on a human papillomavirus immunization program. Canadian Immunization Committee 2007.
61. Fairley C.K., Hocking J.S., Gurrin L.C., Chen M.Y., Donovan B., Bradshaw C.S. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009, 85:499-502.
62. Donovan B., Franklin N., Guy R., Grulich A.E., Regan D.G., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011, 11:39-44.
63. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87:544-547.
64. Bauer H.M., Wright G., Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012, 102:833-835.
65. Comité sur l'immunisation du Québec (CIQ), Comité scientifique ad hoc VPH La Vaccination contre les VPH au Québec: Mise à jour des connaissances et propositions du comité d'experts. Direction des risques biologiques et de la santé au travail 2012, Institut national de santé publique Québec (INSPQ).
66. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
67. Jit M. Reviewer's report on Kohli, M. et al. "Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a HPV-6/11/16/18 vaccine in Canada". BMC Public Health 2012, 12(1):872.
68. Baussano I. Reviewer's report on Kohli, M. et al. "Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a HPV-6/11/16/18 vaccine in Canada". BMC Public Health 2012, 12(1):872.
69. Johnson-Obaseki S., McDonald J.T., Corsten M., Rourke R. Head and neck cancer in Canada: trends 1992 to 2007. Otolaryngol Head Neck Surg 2012, 147:74-78.
70. Chaturvedi A.K., Engels E.A., Anderson W.F., Gillison M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008, 26:612-619.
71. Shiboski C.H., Schmidt B.L., Jordan R.C. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005, 103:1843-1849.
72. Nasman A., Attner P., Hammarstedt L., Du J., Eriksson M., Giraud G., et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma. Int J Cancer 2009, 125:362-366.
73. Comité sur l'immunisation du Québec (CIQ), Comité scientifique ad hoc VPH La Vaccination contre les VPH au Québec: Mise à jour des connaissances et propositions du comité d'experts. Direction des risques biologiques et de la santé au travail 2012, Institut national de santé publique Québec (INSPQ), [Chapitre 2].
74. Shiels M.S., Pfeiffer R.M., Chaturvedi A.K., Kreimer A.R., Engels E.A. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst 2012, 104:1591-1598.
75. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
76. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199:936-944.
77. Romanowski B. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types: end-of-study results. Abstract presented at the 26th international papillomavirus conference 2010.
78. Giuliano A.R., Tortolero-Luna G., Ferrer E., Burchell A.N., de Sanjose S., Kjaer S.K., et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008, 26(Suppl. 10):K17-K28.
79. Brown D.R., Schroeder J.M., Bryan J.T., Stoler M.H., Fife K.H. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999, 37:3316-3322.
80. Aubin F., Pretet J.L., Jacquard A.C., Saunier M., Carcopino X., Jaroud F., et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008, 47:610-615.
81. Butler J.R.G., Kliewer E.V., Demers A.A., Musto G., Lotocki R., Elliott L., et al. The cost of treating anogenital warts in Manitoba, Canada. Abstract presented at the 24th international papillomavirus conference and clinical workshop 2007.
82. Tully S.P., Anonychuk A.M., Sanchez D.M., Galvani A.P., Bauch C.T. Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine 2012, 30:425-435.
83. Altekruse S., Kosary C., Krapcho M.N., Aminou N., Waldron R.W., et al. SEER cancer statistics review, 1975-2007 2010, National Cancer Institute, Bethesda, MD.